Notch signaling plays a role in specifying a cardiac fate but the downstream effectors remain unknown. In this study we implicate the Notch downstream effector HES5 in cardiogenesis. We show transient Hes5 expression in early mesoderm of gastrulating embryos and demonstrate, by loss and gain-of-function experiments in mouse embryonic stem cells, that HES5 favors cardiac over primitive erythroid fate. Hes5 overexpression promotes upregulation of the cardiac gene Isl1, while the hematopoietic regulator Scl is downregulated. Moreover, whereas a pulse of Hes5 instructs cardiac commitment, sustained expression after lineage specification impairs progression of differentiation to contracting cardiomyocytes. These findings establish a role for HES5 in cardiogenesis and provide insights into the early cardiac molecular network.
INTRODUCTION
During embryogenesis, cardiac precursors derive from mesodermal cells that ingress through the primitive streak and segregate shortly after migration of prospective hematopoietic progenitors to the yolk sac (Parameswaran and Tam, 1995) . Signaling pathways governing heart formation are often functional or reactivated in cardiac disease, such as the example of Notch, whose activation after myocardial infarction has been correlated with repair and pro-survival processes (reviewed in Freire et al., 2014) . Thus, understanding the mechanisms underlying cardiac fate is essential in envisaging new strategies for improved cardiac repair/regeneration. Notch signaling is crucial for heart formation, and lossof-function mutations in several pathway components result in severe cardiac phenotypes, including impaired trabeculation and ventricular septal defects (reviewed in Nemir and Pedrazzini, 2008) . Notch signaling is mediated by the interaction of transmembrane receptors (NOTCH1-4) and ligands (JAGGED1 and 2 and DLL1, 3, and 4) expressed on the surface of neighboring cells. Ligand-receptor binding results in the release of the Notch intracellular domain (NICD) which translocates to the nucleus and binds RBP-Jk/CSL, activating transcription of Notch downstream targets. These include members of Hes and Hes-related (also known as Hey) gene families encoding basic helix-loop-helix (bHLH) transcription factors that mediate important Notch functions, such as maintenance of progenitors and binary cell fate decisions (reviewed in High and Epstein, 2008; Kageyama et al., 2007) .
The effects of Notch are dependent on the cellular context and timing of the signal. For example, transient Notch activation in mouse embryonic stem cell (mESC)-derived hemangioblasts redirects differentiation to a cardiac fate, suggesting a role in specifying the cardiac lineage . Likewise, NICD1 expression in nascent mesodermal cells in the embryo (Del Monte et al., 2007) supports a role in mesodermal patterning at the time cardiac progenitors are specified. However, activation of Notch in the early Xenopus heart field (Rones et al., 2000) and in murine cardiogenic mesoderm (Watanabe et al., 2006) suppresses myocardial differentiation.
We aimed to identify NICD1 targets playing a role at the onset of cardiogenesis. We show that Hes5 is expressed in gastrulating mesoderm and instructs cardiac over primitive erythroid fate in mESC-derived mesodermal progenitors, while regulating important cardiac and hematopoietic genes such as Isl1 and Scl. Moreover, after cardiac induction, Hes5 withdrawal is required to allow differentiation to contracting cardiomyocytes. Our results establish a context-and time-dependent role for HES5 in cardiogenesis.
RESULTS

Hes5 Expression during mESC Differentiation and in Gastrulating Embryos Suggests a Role in Mesodermal Patterning Downstream of NICD1
To identify NICD1 targets involved in cardiac specification, we used AinV/Bry-GFP/NICD1 mESCs ) that express NICD1 under the control of a doxycycline (Dox)-inducible promoter and harbor GFP targeted to the Brachyury locus (Bry-GFP), a pan-mesodermal marker. We analyzed the expression of the Notch targets Hes5, Heyl, Hey1, Hey2 and Hes1, at 4, 12, 24, 48 , and 96 hr after activating NICD1 in Bry-GFP + mesodermal cells. Hes5, Heyl, and Hey1 were upregulated, while Hey2 was only increased at later time points and Hes1 was not altered ( Figure 1A ). Hes5 levels were highly increased up to 24 hr followed by a dramatic decrease, suggesting a time-dependent regulation. We then analyzed the expression profile of Hes5 during mESC differentiation to mesodermal derivatives in the absence of NICD1 activation. Hes5 levels increased from day 3.75 (D3.75) to D5, and decreased at D6 ( Figure 1B ). The timing of Hes5 upregulation corresponds to the temporal window in which mesoderm is specified to its derivatives, as demonstrated by the expression profile of mesodermal and early cardiac and hematopoietic regulators ( Figure S1A ). Hes5 expression was also analyzed in early development by whole-mount in situ hybridization in mouse embryos from embryonic day 6.5 (E6.5) to E9.5. Hes5 transcripts were detected in Figure 1 . Expression of the NICD1 Target Hes5 during mESC Differentiation and in Mouse Embryos (A) Real-time qPCR analysis of Hes5, Heyl, Hey1, Hey2, and Hes1 after NICD1 activation in Bry-GFP + cells shows a peak upregulation of Hes5. (B) Hes5 expression profile during mESC differentiation to mesodermal derivatives. Error bars represent mean ± SEM of three experiments. D, day. (C) Whole-mount in situ hybridization for Hes5 in early-streak (ES) and late-bud (LB) embryos (scale bars, 100 mm). Transversal sections at the indicated positions (a and b; scale bars, 50 mm). ant, anterior; pos, posterior; prx, proximal; dis, distal; M, mesoderm; PS, primitive streak; al, alantoid; n, node; nec, neuroectoderm. See also Figure S1 . nascent mesodermal cells of early-streak (ES, n = 6/7) and mid-streak (MS, n = 4/4) embryos (Figures 1C and S1B) . At this early stage, epiblast cells ingressing through the primitive streak are fated to become extraembryonic mesoderm and cranial-cardiac mesoderm (Parameswaran and Tam, 1995) . Hes5 was not expressed (n = 5/8) or was dramatically downregulated (n = 3/8) in late-bud (LB) stage embryos ( Figures 1C and S1B ). Embryos at later stages exhibited Hes5 in ectoderm and neuronal structures as expected ( Figure S1B ). The transient Hes5 expression in gastrulating mesoderm and during mesodermal differentiation in mESCs suggests a time-specific role during early mesodermal specification to cardiac and hemogenic lineages.
Depletion of Hes5 Enhances Primitive Erythropoiesis in mESCs
We asked whether HES5 is a mediator of NICD1 in the specification of a cardiac fate. A fine dissection of early events during embryonic development is technically challenging when using mouse embryos, particularly in the case of a transient expression profile. Hence, we pursued our studies profiting of the robustness of the mESC differentiation system in replicating the early embryo development (reviewed in Murry and Keller, 2008) . For Hes5 depletion, cells were transduced with a short hairpin RNA (shRNA) (shHes5) or a control shRNA targeting Luciferase (shLuc) (Figure 2A ). Interestingly, in Hes5-knockdown (KD) cultures hematopoietic-like cells were predominant, and (L) Real-time qPCR data for cardiac (Tbx5, Gata4, Isl1, Myh6) and hematopoietic (Scl, Gata1) genes in shLuc-and shHes5-transduced cells at D4.75 and D8. Error bars represent mean ± SEM of three (or five in K) experiments. *p < 0.05, **p < 0.01, ***p < 0.001. See also Movies S1 and S2.
only rare contracting areas emerged ( Figure 2B and Movie S1). In contrast, control cultures presented cardiomyocytes and hematopoietic cells ( Figure 2B and Movie S2).
In the developing vertebrate embryo, the first wave of hematopoiesis occurs in the yolk sac and contributes principally primitive erythroid cells (reviewed in Tavian and Peault, 2005) . To investigate the role of HES5 in the emergence of the hematopoietic lineage, we carried out a timecourse flow-cytometry analysis from D2 to D5.75 of in vitro differentiation following Hes5-KD. Primitive mesodermal progenitors co-express FLK1 and platelet-derived growth factor receptor a (PDGFRa), whereas in vascular/ hematopoietic mesoderm PDGFRa expression is downregulated (Kataoka et al., 2011 Figure 2H ), particularly CD41 + TER119 + early erythroid precursors ( Figure 2I ) (up to 4.3-and 12.9-fold increase, respectively). In addition, a higher percentage of cells expressing the pan-hematopoietic marker CD45 was observed in Hes5-KD cultures (up to 2.5-fold increase) ( Figure 2J ). To confirm that depletion of Hes5 promoted hematopoiesis, we performed colony-forming unit (CFU) assays. No colonies emerged in both control and Hes5-KD cultures from cells plated in methylcellulose-based medium at D3.75 (not shown).
Hes5-KD cells plated at D4.75 created a significantly higher number of primitive erythroid (EryP) colonies (2.3-fold) ( Figure 2K ), consistent with the increased frequency of erythroid progenitors emerging earlier during differentiation. We did not observe an effect on the differentiation to other hematopoietic lineages ( Figure 2K ). These results suggest that loss of Hes5 in mESCs favors the emergence of the first wave of hematopoiesis, which primarily contributes EryP. Following these observations, expression of cardiac genes (Tbx5, Gata4, Isl1, and Myh6) and hematopoietic regulators (Scl and Gata1) was analyzed. Cardiac genes were downregulated in Hes5-KD cells (varying from 2.0-fold up to 12.5-fold), especially Gata4 at D4.75 and Isl1 at D8 of differentiation; Scl expression was similar to control at these stages and the erythroid master regulator Gata1 was significantly upregulated at D4.75 (4.8-fold) and comparable with the control at D8 ( Figure 2L) .
Altogether these data demonstrate that loss of Hes5 in mESCs enhances primitive erythropoiesis, and support a role in the regulation of cardiac versus primitive erythroid fate in early mesodermal progenitors.
HES5 Instructs Cardiac Over Primitive Erythroid Differentiation in mESC-Derived Mesodermal Cells
To better understand the role of HES5 in the specification of mesodermal lineages, we used a Dox-inducible gain-offunction system to express exogenous FLAG-tagged Hes5 ( Figure 3A ) in reverse tetracycline transactivator (rtTA)-expressing AinV/Bry-GFP mESCs. Given the contextdependent role of HES factors, we induced pulses of Hes5 at distinct stages of differentiation (D2-D3, D3-D3.75, D3.75-D4.75, and D4.75-D5.75) and quantified the number of contracting foci. Interestingly, only activation at D3.75 significantly promoted the emergence of contracting foci (from 3.4-fold up to 5.0-fold increase) ( Figure 3B ; Movies S3 and S4), correlating with the results on the endogenous Hes5 levels ( Figure 1B ). Next, we investigated the effect of Hes5 induction at D3.75 on hematopoietic differentiation. After 48 hr of Dox treatment, the number of cKIT + CD41 + and cKIT À CD41 + cells was decreased (1.9-and 2.1-fold, respectively) ( Figures 3C and 3D ). Importantly, Hes5 overexpression led to a dramatic reduction in CD41 + TER119 + early erythroid precursors (10.4-fold) (Figures 3C and 3D) and Gata1 downregulation (4.2-fold) (Figure 3E) . Moreover, cells induced at D3.75 and subjected to CFU assays at D4.75 or at D5.75 created a lower number of EryP colonies (2.1-and 2.8-fold, respectively) (Figure 3F) , corroborating the effect on primitive erythropoiesis observed in Hes5-KD cells. Both time points showed similar potential of differentiation to other hematopoietic lineages that was not altered after Hes5 induction ( Figure 3F ). Next, we addressed whether preferential cardiac fate results from a selective or instructive action in primitive mesodermal cells. Proliferation and apoptosis were analyzed after Hes5 activation in Bry-GFP + FLK1 + PDGFRa + cells isolated at D3.75. The results indicate that HES5 does not promote the selection of particular subsets of progenitors, as non-induced and induced cultures contained a similar percentage of proliferative ( Figure 3G ) and apoptotic cells ( Figure 3H ) after 24 and 36 hr, respectively. Together our data demonstrate a time-specific and instructive role for HES5 in specifying early mesodermal cells to a cardiac over a primitive erythroid fate.
HES5 Regulates Cardiac and Hematopoietic Genes in
Mesodermal Cells Including Isl1 and Scl HES proteins regulate transcription by DNA bindingdependent and -independent mechanisms; the latter includes prevention of DNA binding by lineage-specific bHLH activators (reviewed in . To gain further mechanistic insight into how HES5 promotes a cardiac fate, we investigated whether HES5 and SCL, also a bHLH protein, form a heterodimeric complex with impaired DNA binding abilities. No protein-protein interaction between HES5 and SCL was found by immunoprecipitation ( Figure S2A ). To identify genes bound by HES5, we performed chromatin immunoprecipitation combined with DNA sequencing (ChIP-seq) 48 hr after Hes5 induction at D3.75 (Figures S2B and S2C ; Table S1 ). Using the Panther classification system, cardiovascular and vascular/hematopoietic developmental processes and the Wnt pathway were highly enriched categories (Figure 4A and Table S2 ). The expression of cardiac (Isl1, Gata4, Gata6, and Tbx1) and hematopoietic (Runx1, Lmo2, and Scl) genes bound by HES5 according to the ChIP-seq data ( Figure S2D ) was analyzed. Isl1 and Scl responded significantly to Hes5 induction, being upregulated (5.3-fold) and downregulated (2.1-fold), respectively, 24 hr after Dox addition, and further increased (8.7-fold) and decreased (3.6-fold), respectively, after 48 hr. The other genes showed no or only moderate alteration in the mRNA levels ( Figure 4B ). HES5 binding peaks were found 0.24 kb upstream of the Isl1 transcription start site (TSS) and 3.8 kb downstream of the Scl TSS ( Figure 4C ). Moreover, an increase in the percentage of ISL1 + cells (4.4-fold) ( Figure 4D ) and decrease of SCL + cells (3.8-fold) ( Figure 4E) 48 hr after Hes5 induction reflected the preferential choice toward cardiac over hematopoietic lineage. Together, these findings show that HES5 binds regulators of vascular/ hematopoietic and heart development, including Scl and Figure S2 ; Tables S1 and S2.
Isl1, which likely mediate in part the preferential cardiac cell fate decision downstream of HES5.
Sustained Hes5 Expression after Cardiac Induction Impairs Differentiation to Contracting Cardiomyocytes Our results showed that a specific pulse of Hes5 induction from D3.75 to D4.75 enhanced cardiac differentiation ( Figure 3B) . Moreover, the transient profile of Hes5 expression in differentiating mESCs ( Figures 1A and 1B) and gastrulating embryos ( Figure 1C ), suggest that after inducing a cardiac fate Hes5 downregulation might be required. Thus, we evaluated the effect of increasing periods of Dox treatment, i.e., D3.75-D4.75, D3.75-D5.75, D3.75-D7.75, and D3.75-D10 (sustained), on cardiac differentiation. Activation for 24 and 48 hr significantly enhanced the number of contracting foci, whereas sustained Hes5 almost abrogated the emergence of contracting foci (Figure 5A) . We asked whether a sustained Hes5 induction blocks differentiation to contracting cardiomyocytes. Expression of structural genes of cardiomyocytes (Myh6 and cTnT) and cardiac progenitor genes (Isl1, Tbx1, Tbx5, Nkx2.5, Gata4, and Gata6) was evaluated at D10 in cells subjected to pulse (24 hr) or sustained Hes5 activation. As expected, Hes5 was upregulated after sustained Dox, whereas pulse-activated cells showed levels comparable with control levels ( Figure 5B ). Tbx5 and Isl1, usually associated with first and second heart field progenitors (FHF and SHF), respectively, were significantly upregulated (3.5-and 5.8-fold, respectively) after sustained Hes5 expression ( Figure 5C ). Myh6 and cTnT mRNA levels were upregulated (3.2-and 3.4-fold, respectively) (Figure 5C ) and cTNT protein detection was more prominent ( Figure 5D ) in cells subjected to Hes5 pulse, but were comparable with control levels after sustained induction. To confirm whether sustained Hes5 activation impairs cardiomyocytic differentiation, we removed Dox after 10 days of treatment. The number of contracting foci at 48 hr after Dox withdrawal was not significantly different from pulse-activated cultures and was significantly increased compared with non-induced (3.8-fold) and sustained Dox treatment (4.4-fold) conditions ( Figure 5E ). Our results demonstrate that after cardiac specification, Hes5 withdrawal is required for completing differentiation to contracting cardiomyocytes.
DISCUSSION
Here we established a role for HES5 in instructing a cardiac fate while repressing the hemogenic program in early mesodermal progenitors. In Hes5-KD the first hematopoietic wave of primitive erythropoiesis overrides the cardiac potential, whereas a stage-specific Hes5 overexpression results in enhanced cardiac differentiation. Importantly, we show Hes5 expression in early mesoderm at the onset of gastrulation, which closely resembles the transient pattern of Mesp1 (E6.5-E7.0) and correlates with the time cardiac progenitors are specified (Saga et al., 1999) . Moreover, the unaltered frequency of cell proliferation and apoptosis after Hes5 induction further imply an instructive rather than a selective role in primitive mesoderm.
To date, a role for HES5 in cardiac development has not been demonstrated. Hes5-null embryos have no apparent cardiovascular phenotype, but to our knowledge studies specifically addressing heart malformations in the mutants have not been performed. Nonetheless, HES5 function may be compensated by another HES/HEY protein, as functional redundancy between members of these families has been shown at later stages of heart morphogenesis Kokubo et al., 2005) . For example, Hey1, Hey2, and Heyl play important roles in heart formation but, with exception of Hey2-null mice, only the double mutants show cardiac abnormalities (reviewed in Nemir and Pedrazzini, 2008 ).
Repression of the hematopoietic/erythroid program to ensure cardiac fate determination in mesodermal cells has been previously demonstrated (Caprioli et al., 2011) . Our data show that HES5 binds regulators of vascular/hematopoietic and heart development, including Scl and Isl1, which likely mediate in part preferential cardiac cell fate decision downstream of HES5. Homozygous Isl1-null mice have several heart abnormalities, dying by E10.5 (Cai et al., 2003) , and Isl1 overexpression in mESCs enhances specification of cardiac progenitors (Dorn et al., 2015) . ISL1 has been referred as an SHF marker; however, the expression in pre-cardiac mesoderm and in the cardiac crescent, as well as the contribution to derivatives of both heart fields, suggest ISL1 to be a pancardiac progenitor marker (Brade et al., 2007; Ma et al., 2008; Prall et al., 2007; Yuan and Schoenwolf, 2000) . Scl-deficient embryos show ectopic cardiogenesis in prospective hemogenic endothelium (Van Handel et al., 2012) and die by E9.5, lacking hematopoiesis in the yolk sac (Robb et al., 1995) .
In the embryo brain, HES5 maintains undifferentiated neural stem cells, which are then capable to differentiate after downregulation (Ohtsuka et al., 2001) . We demonstrate a similar role in cardiogenesis, since sustained Hes5 impairs the emergence of contracting colonies, whereas downregulation after cardiac induction allows cardiomyocytic differentiation. These findings further imply a transient role for HES5 during early mesodermal specification to its derivatives, which is corroborated by the pattern of expression we observed in gastrulating embryos. Thus HES5 plays a dual role in cardiogenesis, promoting cardiac fate specification as a pulse, while impairing differentiation to cardiomyocytes when activated in a sustained manner. Our results are in line with previous evidence for an inhibitory effect of Notch in cardiogenesis, which appears to correlate with activation at the level of development and maturation of the cardiac lineage but not upon its induction Liu et al., 2014; Rones et al., 2000; Watanabe et al., 2006) .
Interestingly, and suggesting a conserved mechanism throughout evolution, esr9, a member of the Hes5-like subfamily expressed in Xenopus (Li et al., 2003) , regulates the timing of heart field specification, repressing cardiac differentiation when induced after gastrulation (Miazga and McLaughlin, 2009 ).
Herein, we identified an important player downstream of NICD1 that sets in motion cardiogenesis and represses hematopoietic commitment in early mesodermal precursors. Notably, the effect of Hes5 on primitive erythropoiesis is consistent with the required inhibition of Notch signaling for development of this lineage , while NOTCH1 is essential for definitive hematopoiesis (Kumano et al., 2003) . Furthermore, our data reinforce the context-specific and time-dependent nature of HES proteins, i.e., not only the timing of induction but also the duration of the signal affects cell fate determination and differentiation.
Hence, we propose a model in which transient HES5 activity in early mesoderm instructs the timing of cardiac fate specification while repressing the first wave of hematopoiesis. Thus in the absence of this signal, commitment to EryP is favored by default. Moreover, after a pulse of Hes5 instructing a cardiac fate, downregulation is required for emergence of contracting cardiomyocytes ( Figure 6A ). Our observation of Hes5 transient expression in early embryo mesoderm at the time cardiac and hematopoietic progenitors are specified strongly indicates that a similar mechanism is likely to occur during embryogenesis ( Figure 6B ). Although challenging given the risk for the successful progression of embryo development, further in vivo analyses, including lineage tracing of the progeny derived from the transient Hes5-expressing nascent mesoderm, will be required to ultimately demonstrate a role in specifying cardiac fate in the embryo.
In conclusion, this study establishes a role for HES5 in cardiogenesis, contributing further insight into the complex signaling that regulates cardiac fate determination and paving the way for future mechanistic studies aimed at the validation and comprehension of how HES5 imparts heart formation in the developing embryo.
EXPERIMENTAL PROCEDURES mESC Lines
The AinV/Bry-GFP/NICD1 and AinV/Bry-GFP mESC lines were a kind gift from Dr. Gordon M. Keller and Dr. Valerie Gouon-Evans.
mESC Culture and Differentiation mESCs were maintained in the absence of feeders on 0.1% gelatincoated (Sigma-Aldrich) plates in the presence of 15% fetal bovine serum (FBS) (BenchMark, catalog lot no. A00D05C) and 1,000 U/mL leukemia inhibitory factor (Esgro, Millipore). Differentiation to mesoderm was induced as previously described (Gadue et al., 2006; Kattman et al., 2011) with few modifications. In brief, mESCs were plated at 1-2 3 10 5 cells/mL in serum-free differentiation medium in ultra-low-attachment 6-well plates (Corning) for 48 hr to allow formation of embryoid bodies (EBs). After this period EBs were dissociated using TrypLE Express (Gibco, Life Technologies) and plated at 1.5-4 3 10 5 cells/mL in the presence of 5 ng/mL human vascular endothelial growth factor, 25 ng/mL human activin A, and 1 ng/mL human bone morphogenetic protein 4 (all from R&D Systems) for 42 hr. For cardiac differentiation, D3.75 cells were dissociated and reaggregated at 2 3 10 5 cells/mL in StemPro-34+StemPro-Nutrient Supplement (Gibco, Life Technologies) medium with supplements in ultra-low-attachment 24-well plates (Corning). After 24 hr the aggregates were replated on gelatin-coated 24-well plates as previously described . Doxycycline (Dox) (1 mg/mL; Sigma-Aldrich) was added to the medium at indicated time points. For CFU assays, D3.75 cells were plated in StemPro-34 medium with supplements for 24 or (B) A similar mechanism is likely to take place in the embryo. Hes5 is expressed in the nascent mesoderm of streak-stage embryos at the time cardiac and hematopoietic progenitors are specified ($E6.5). Around E7.5 cardiac progenitors that left the primitive streak organize to form the cardiac crescent while hematopoietic progenitors have migrated to the yolk sac, coinciding with downregulated Hes5 expression in the mesoderm. shRNA Design shRNA sequences were obtained from The RNAi Consortium library database. shRNA oligos were synthesized by Integrated DNA Technologies, annealed, and cloned into AgeI/EcoRI sites of the lentiviral-based shRNA expression vector pLKO.1 (Addgene) (Moffat et al., 2006) according to the supplier's protocol. shRNA constructs were confirmed by sequencing and are listed in Table S3 .
Lentivirus Production and mESC Transduction
Lentiviral-based shRNA vectors and pCMV-dR8.2 (packaging) and pCMV-VSVG (envelope) plasmids were co-transfected into HEK293T cells using the calcium phosphate method described in detail in Supplemental Experimental Procedures. Viral supernatants were harvested after 36, 48, and 72 hr, filtered (0.45 mm), and concentrated with Amicon ultra-centrifugal filter units (Millipore). mESCs were incubated overnight with virus in medium supplemented with polybrene (8 mg/mL, Sigma-Aldrich) and cultured in fresh medium for 4 days. After this period, cells were cultured in medium supplemented with 5 mg/mL blasticidin for an additional 4 days. For Hes5 overexpression AinV/Bry-GFP mESC were infected with a lentiviral pTRE-IRES-Bsd R vector expressing FLAG-tagged Hes5 under the control of a tetracycline response element promoter. After blasticidin selection and single-cell sorting, colonies were screened for FLAG expression after Dox treatment.
Gene Expression Analysis
RNA was extracted using TRIzol reagent (Invitrogen) according to the manufacturer's instructions, and cDNA was synthesized using PrimeScript RT reagent kit (Takara Bio). Real-time qPCR was performed using iQ Sybr Green Supermix (Bio-Rad) and gene-specific primers (Table S4) . Reactions were carried out in triplicate on the iCycler iQ5 Real-Time PCR system (Bio-Rad). Relative gene expression was normalized to glyceraldehyde-3-phosphate dehydrogenase (Gapdh) expression.
Flow Cytometry
Cells were incubated with phycoerythrin (PE)-conjugated anti-FLK1 (Avas 12a1, BD Biosciences) and anti-TER119 (TER-119, Immunotools); allophycocyanin-conjugated anti-PDGFRa/CD140a (APA5, BioLegend), anti-cKIT/CD117 (ACK2, eBioscience), and anti-CD144/VECAD (eBioBV13, eBioscience); and PE-Cyanine7-conjugated anti-CD41 (MWReg30, eBioscience) and anti-CD45 (30-F11, eBioscience) at 1:100 dilution at 4 C for 30 min in PBS containing 3% FBS. All of the antibody clones are commonly used and proven in the field (Chan et al., 2013; Haas et al., 2012; Pereira et al., 2016) ; gating was determined using unstained controls. For ISL1 detection, the FOXP3/Transcription Factor Staining Buffer Set (eBioscience) was used following the manufacturer's instructions. In brief, cells were fixed and permeabilized in the fixation/permeabilization solution for 45 min at room temperature. Cells were washed in permeabilization buffer and incubated with PE-conjugated anti-ISL1 (Q11-465, BD Biosciences) at 1:100 dilution for 60 min at room temperature. PE-conjugated anti-mouse immunoglobulin G antibody was used as control. Flow-cytometry acquisition was performed using FACSCanto II (BD Biosciences) and analyzed using FlowJo software. For cell sorting, cells were resuspended in PBS containing 2% FBS, 25 mM HEPES, and 1 mM EDTA, and sorted using Mo-Flo (DakoCytomation) or FACS Aria (BD Biosciences) cell sorters.
Cell Proliferation and Cell Apoptosis Analyses
Cell proliferation was assessed using the Click-iT Plus EdU cell proliferation kit (Molecular Probes). Cells were incubated with 10 mM 5-ethynyl-2 0 -deoxyuridine (EdU) for 5 hr, dissociated with TrypLE Express, and fixed with ice-cold 70% ethanol for 30 min at 4 C.
Next, samples were washed with 0.1% Tween 20 and incubated for 30 min at room temperature with Click-iT Plus reaction cocktail. After washing in 0.1% Tween 20, cells were incubated with 50 mg/mL propidium iodide and 10 mg/mL RNase for 30 min before acquisition. Apoptosis was assessed using the Annexin V detection kit (eBioscience) according to the manufacturer's protocol. In brief, cells were gently dissociated with StemPro Accutase Cell Dissociation Reagent (Gibco, Life Technologies) for 5 min, and washed in PBS and then in Binding Buffer provided by the kit. V450-conjugated Annexin V was incubated at 1:20 dilution for 15 min at room temperature. After washing in Binding Buffer, samples were incubated with 7-aminoactinomycin D (7-AAD) viability staining solution. Flow-cytometry acquisition was performed using FACSCanto II (BD Biosciences) and analyzed using FlowJo software.
Immunofluorescence
For FLAG and cTNT detection, cells were fixed with 4% paraformaldehyde (PFA) for 20 min and permeabilized with 0.2% Triton X-100 in PBS for 5 min. After blocking in PBS containing 4% FBS and 1% BSA for 60 min, samples were incubated with mouse anti-FLAG (M2, Sigma-Aldrich) at 1:100 dilution or mouse anticardiac troponin T (13-11, NeoMarkers/Thermo Scientific) at 1:500 dilution for 120 min, followed by anti-mouse 488 for 60 min. For SCL staining, cells were dissociated, cytospun into slides, and fixed with cold methanol for 2 min. After permeabilization with 1% Triton X-100 in PBS for 5 min, blocking was performed using 4% FBS and 1% BSA in PBS for 60 min. Incubation with goat anti-SCL (C21, Santa Cruz Biotechnology, sc-12984X) at 1:10,000 dilution was carried out for 90 min and followed by incubation with secondary antibody donkey anti-goat 568 for 45 min. For nuclei staining, samples were incubated with DAPI at 0.5 mg/mL or mounted in Vectashield with DAPI (Vector Laboratories). Images were acquired using Leica DMI4000 (Leica) or Axiovert 200 (Zeiss) microscopes.
Whole-Mount In Situ Hybridization
C57BL/6 (Charles River) pregnant females and embryos were used in this study. All animal work was approved by the i3S Animal
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Ethics Committee and by the Direcção Geral de Veterinária (permit 022793), and is in conformity with the Directive 2010/63/EU of the European Parliament. Humane end points were followed in accordance to the OECD Guidance Document on the Recognition, Assessment, and Use of Clinical Signs as Humane End Points for Experimental Animals Used in Safety Evaluation. The day of the vaginal plug was designated embryonic day (E) 0.5(E0.5). Embryos were staged according to the dissection time and morphology as previously described (Downs and Davies, 1993) . E6.5-E9.5 embryos were fixed overnight at 4 C in 4% PFA at pH 7.4 and whole-mount in situ hybridization was performed as previously described (Henrique et al., 1995) . In brief, embryos were dehydrated in a graded series of methanol, treated with 10 mg/mL Proteinase K (Sigma-Aldrich), and post-fixed for 20 min in 4% PFA and 0.1% glutaraldehyde. Embryos were incubated with digoxigenin-labeled Hes5 antisense probe (a gift from Dr. Domingos Henrique) overnight at 65 C and with anti-digoxigenin antibody at 1:2,000 dilution (Roche) overnight at 4 C. Detection was performed using NBT/BCIP (Roche). Photographs were acquired using an Olympus SZX16 stereomicroscope. For cryosectioning, embryos were dehydrated in a sucrose gradient (4% followed by 15%), embedded in 7.5% gelatin, and frozen. Tissue sections (12 mm) were obtained using a Leica cryostat, mounted in Fluoromount (Sigma-Aldrich), and photographed using an Axiovert 200 (Zeiss) microscope.
ChIP-Seq Sample Preparation and Analysis
Sample preparation and analysis were performed as previously described (Waghray et al., 2015) . Procedures are described in detail in Supplemental Experimental Procedures.
Statistical Analysis
Pooled data from biological replicates is presented as mean ± SEM. Statistical significance was determined by unpaired two-tailed t test (comparison between two groups) or ANOVA with post hoc Tukey's test (comparison between three or more groups) using GraphPad Prism. p < 0.05 was considered statistically significant.
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ChIP-seq data are deposited in NCBI-GEO database under accession number GEO: GSE64540. 
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